Harvard Apparatus Regenerative Technology Inc. (HRGN)
| Previous close | 2.2000 |
| Open | 2.6300 |
| Bid | 2.6300 x 0 |
| Ask | 2.6800 x 0 |
| Day's range | 2.6300 - 2.6800 |
| 52-week range | 2.1300 - 6.0000 |
| Volume | |
| Avg. volume | 1,225 |
| Market cap | 38.364M |
| Beta (5Y monthly) | -1.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5800 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireHarvard Apparatus Regenerative Technology Reports First Quarter 2024 Financial Results and Recent Business Highlights
Entered into securities purchase agreements with accredited investors for a $1.5 million private investment in public equity (PIPE) financing. The transaction closed on April 15, 2024.Received $0.5 million in convertible debt from Company’s CEO in February 2024. Holliston, MA, May 13, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technolog
- GlobeNewswire
Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Established a Research Collaboration with the McGowan Institute for Regenerative Medicine at the University of Pittsburgh to Study the Repair and Regeneration of the Colon following ColectomyEstablished a Collaboration with Hugh Taylor, MD, chair of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine to Repair and Regenerate the UterusActivated the second clinical trial site with the University of Michigan in August 2023 to expand the screening of patients.Received approval
GlobeNewswireHarvard Apparatus Regenerative Technology and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Establish a Research Collaboration to Study the Repair and Regeneration of the Colon following Colectomy
Holliston, MA, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today announced that it officially executed a sponsored research agreement (SRA) with Drs. Stephen Badylak, George Hussey and Vincent Anto at the McGowan Institute for Regenerative Medicine, a cent
